drugset / Trial / NCT00399165

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165

Phase 1/2 Completed 20 enrolled University of Washington GlaxoSmithKline · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval

Timeline

Start
2006-11
Primary completion
2007-05
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Testosterone Enanthate Small molecule 400 mg Oral
Comparator Testosterone Enanthate Small molecule 800 mg Oral
Comparator Dutasteride Small molecule 0.5 mg Oral

Indications

No indication recorded.